טוען...
Cost analysis of the management of brain metastases in patients with advanced ALK+ NSCLC: alectinib versus crizotinib
AIM: To estimate management cost of NSCLC ALK+ patients with and without brain metastasis (BM), and to compare annual costs in patients treated with alectinib or crizotinib. METHODS: Management cost/year (€ 2018) in patients with and without BM was estimated with disaggregated resource consumption p...
שמור ב:
| הוצא לאור ב: | Lung Cancer Manag |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Future Medicine Ltd
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7110588/ https://ncbi.nlm.nih.gov/pubmed/32256712 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/lmt-2019-0011 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|